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Abstract
Background: Recruiting large and representative samples of adolescent and young adult (AYA) cancer survivors is
important for gaining accurate data regarding the prevalence of unmet needs in this population. This study aimed
to describe recruitment rates for AYAs recruited through a cancer registry with particular focus on: active clinician
consent protocols, reasons for clinicians not providing consent and the representativeness of the final sample.
Methods: Adolescents and young adults aged 14 to19 years inclusive and listed on the cancer registry from
January 1 2002 to December 31 2007 were identified. An active clinician consent protocol was used whereby the
registry sent a letter to AYAs primary treating clinicians requesting permission to contact the survivors. The registry
then sent survivors who received their clinician’s consent a letter seeking permission to forward their contact
details to the research team. Consenting AYAs were sent a questionnaire which assessed their unmet needs.
Results: The overall consent rate for AYAs identified as eligible by the registry was 7.8%. Of the 411 potentially
eligible survivors identified, just over half (n = 232, 56%) received their clinician’s consent to be contacted. Of those
232 AYAs, 65% were unable to be contacted. Only 18 AYAs (7.8%) refused permission for their contact details to be
passed on to the research team. Of the 64 young people who agreed to be contacted, 50% (n = 32) completed
the questionnaire.
Conclusions: Cancer registries which employ active clinician consent protocols may not be appropriate for
recruiting large, representative samples of AYAs diagnosed with cancer. Given that AYA cancer survivors are highly
mobile, alternative methods such as treatment centre and clinic based recruitment may need to be considered.
Background
Importance of research for improving cancer control
Research plays an important role in the advancement of
cancer prevention, screening, treatment and follow-up
care [1-3]. It has led to improvements in morbidity and
mortality for people with cancer over the last 20 years
[1]. The degree to which cancer research findings are
generalisable to the wider cancer population is, in part,
dependent upon the representativeness of the study
sample recruited [4]. One of the challenges facing popu-
lation health research in cancer is the recruitment of
large and representative samples of participants in a
timely and cost efficient manner.
Cancer registries as a means to access representative
groups of cancer survivors
Cancer registries are a potential mechanism for recruit-
ing population-based samples of cancer survivors for
research [5]. In many developed countries cancer regis-
tries are supported by Public Health Acts or other legisla-
tion [6-8]. As a consequence, notification of any cancer
diagnosis by hospitals, general practitioners (GPs), or
pathology units may be legally required. Having a centra-
lised source for recruiting a sample of cancer survivors
has advantages, especially when conducting research with
low incidence cancer populations such as adolescents
and young adults (AYAs) [5].
Adolescents and young adults aged 14 to 19 years
account for approximately 0.5% of the total population
diagnosed with invasive cancers in Europe and North
America [9]. The types of cancer most frequently diag-
nosed in AYAs differ to those diagnosed in children or
older adult cancer populations. The most common cancers
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thyroid and testicular cancer [10], with these cancers also
having high survival rates (5 year relative survival rate of
>80%) [9]. Data from a state-based cancer registry in Aus-
tralia showed that the proportion of survivors aged 14 to
19 years who were reported to be diagnosed with invasive
cancers for the period 2002-2007 was slightly lower than in
Europe and North America (0.4% of all new cases notified
to the registry or 719 new cases in total) [11]. Of all AYA
cancers diagnosed, Hodgkin lymphoma (15%), melanoma
of the skin (15%), leukaemia (14%), invasive brain tumours
(8%), testicular cancer (8%) and bone cancers (8%)
accounted for the highest proportions [11].
For those cancer registries which are population-
based, the sample of AYA cancer survivors recruited
from the registry should reasonably represent the distri-
bution of all AYA cases diagnosed. However, depending
on the timing of recruitment with respect to the time
which has lapsed since the individual’s diagnosis, AYAs
who have cancers with poor survival rates such as bone
cancer and invasive brain tumours may be under-repre-
sented in research studies. Nevertheless, in the case of
low incidence cancer populations such as AYAs, regis-
tries offer potential access to most cases through a sin-
gle access point and may remove the need for
researchers to recruit survivors from multiple sites [5].
Process for recruitment of research participants through
cancer registries
Depending on privacy legislation, there can be up to
three stages of consent required when recruiting cancer
survivors through registries for research studies [12]. At
each stage the number of potentially eligible participants
may be reduced, thereby decreasing the size and repre-
sentativeness of the final sample.
In the first stage of recruitment, the registry may contact
the responsible clinician and request a professional judge-
ment as to whether the survivor is well enough for the reg-
istry to approach. Clinician consent can be active or
passive, depending on the protocols in place within the
registry [13,14]. Active consent requires clinicians to con-
firm the suitability of all identified cancer survivors prior
to the registry contacting the survivor [13,14]. Passive con-
sent requires the clinician to respond to the registry only if
an identified survivor should not be contacted. If the clini-
cian does not respond within a specified time period, clini-
cian consent is inferred and the registry can proceed with
contacting the cancer survivor [13,14].
The second stage of the recruitment process may
require the cancer survivor to grant consent for the regis-
try to provide their contact details to the researchers.
Survivor consent can also be active or passive [12]. Active
consent requires survivors to provide written or verbal
consent if they wish to be contacted [12,14]. Passive
consent allows all survivors to be contacted unless they
opt-out by providing written or verbal notification that
they do not wish contact to occur [12]. The registry can
then provide the contact details of consenting eligible
individuals to the research team [12,14]. In the third
stage of recruitment the researchers contact survivors in
accordance with their approved research protocol and
request participant consent to take part in the research.
Recently, the authors attempted to recruit a popula-
tion-based sample of AYAs with cancer to participate in
a research study requiring the completion of a paper
and pencil questionnaire to assess their unmet needs.
Adolescents and young adults with cancer have pre-
viously been identified in the literature as a vulnerable
population group reporting high levels of physical, psy-
chological and social distress [15-18]. There is a need to
understand aspects of their quality of life and unmet
needs, as well as to identify risk factors for significant
problems in these domains [19-21].
Recruitment was conducted through a state-based
cancer registry in Australia which uses an active clini-
cian and survivor consent process. The aim of this
paper is to describe the resulting registry recruitment
rates and to illustrate: 1) the impact of active clinician
and survivor consent protocols on recruitment rates at
stage 1, 2 and 3 of recruitment; 2) reasons for clinicians
not providing consent to contact survivors; and 3) the
representativeness of the final sample recruited com-
pared with the overall AYA cancer survivor population.
Methods
Setting
This study was approved by the Human Research Ethics
Committees of the University of Newcastle and the Cancer
Institute NSW. A cross-sectional study design was used to
recruit AYAs diagnosed with cancer through a state popu-
lation-based cancer registry in Australia. Under the Public
Health Act for the state, notification of malignant neo-
plasms is a statutory requirement for all public and private
hospitals, departments of radiation oncology, nursing
homes, pathology laboratories, out-patient departments
and day procedure centres. Notifications of cancer in resi-
dents of the relevant state, who are diagnosed and treated
outside of the state, are also received from other state and
territory cancer registries. Demographic information and
clinical details about the cancer and treating clinician are
collected from notifiers [14].
Participants
Adolescents and young adults listed on the registry were
eligible to participate in the study if they were: 1) diag-
nosed with an invasive cancer between the ages of 14 to
19 years inclusive; 2) diagnosed between 1 January 2002
and 31 December 2007 inclusive; 3) residents of the
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clinician as: 4) having a life expectancy of at least
12 months; 5) physically and mentally able to complete
the survey; and 6) sufficiently literate in English.
The age range used to define AYAs varies across the lit-
erature and ranges from 10 to 40 years [22-24]. In this
study the upper age limit of 19 years was selected, as the
World Health Organisation (WHO) defines adolescents as
being between 10-19 years of age [23]. The lower limit of
14 years was chosen because, in Australia, AYAs aged 14
years and older have the legal right to make their own deci-
sions about the type of health care they receive [25]. Survi-
vors who did not reside in the same state as the registry
could not be included as ethics approval was only granted
to contact residents of that state. Adolescents and young
adults diagnosed with non-invasive cancers, such as non-
melanoma skin cancer (NMSC), were excluded for two
reasons: 1) notification of NMSC is not legally required in
most Australian states, with the exception of Tasmania
(TAS), therefore records for NMSC listed on other state
cancer registries are not complete or representative of the
population; and 2) it was expected that the number of sur-
vivors with NMSC would be very small as most cases are
diagnosed in those aged 20 years and older [11].
Procedure
A description of the survivor recruitment protocol used
in the registry is presented in Figure 1[14]. Prior to con-
tacting clinicians, the vital status of all potentially eligi-
ble participants was confirmed by cross checking
registry data with the death register for the state.
Stage 1- Clinicians consent to contact survivors
A letter was sent to identified AYA cancer survivors’
primary treating clinicians (as recorded on the registry)
to inform them about the study, confirm eligibility and
request permission to contact the eligible survivor. Clin-
icians who did not respond to the letter within two
weeks were telephoned by the registry at two-weekly
intervals, up to five times, to determine the eligibility of
the identified AYAs.
Stage 2 - Survivors consent to pass on contact details
Adolescent and young adult survivors whose clinicians
consented for them to be contacted were sent a project
information letter and a “consent to be contacted form”
by the registry, seeking written permission to forward
the survivor’s contact details to the research team. Ado-
lescents and young adults were encouraged to discuss
their possible involvement in the study with their par-
ents and/or primary treating clinicians. Survivors who
had not responded within two weeks of receiving their
initial letters were sent reminder letters by the registry.
Survivors who had not responded within two weeks of
receiving the reminder letters received follow-up tele-
phone calls at the four-week interval. Up to two
attempts to contact survivors by telephone were made.
The registry provided the researchers with the contact
details of AYAs who agreed to be contacted.
Stage 3 - Survivors consent to participate
The researchers sent AYA cancer survivors who agreed to
be contacted a letter of invitation, a study information sheet
and a questionnaire which asked about any unmet needs
they may have experienced in the last month. Unmet needs
related to: daily life; education; work; relationships; feelings;
cancer treatment centre; cancer treatment staff; and infor-
mation were explored. Survivors who had not returned
questionnaires within two weeks of receiving them were
sent reminder letters. Survivors who had not returned ques-
tionnaires within two weeks of receiving reminder letters
received follow-up telephone calls at the four week interval.
Up to two attempts to contact survivors by telephone were
made. Return of the questionnaire was taken as implied
consent to participate in the study.
Analysis
Proportions were calculated to estimate survivor consent
rates overall, and at each stage of recruitment. Fisher’s
exact test was performed using Stata Version 11 statisti-
cal software[26] to identify whether there were any sig-
nificant differences between non-participants (AYAs
who were unable to be contacted or did not provide
consent) and the final sample.
Data from the registry indicated that there were 468
potentially eligible survivors. Assuming a 75% consent
rate at each stage, 351 survivors would receive clinician
consent at Stage 1, 263 survivors would consent to be
contacted at Stage 2 and 197 survivors would consent
by returning a questionnaire at Stage 3. The anticipated
sample size of approximately 200 survivors would allow
the estimation of consent rates with 95% confidence
intervals within ±7% and a detection of differences in
binary variables between the groups of 25% with 80%
power at the 5% significance level.
Results
Recruitment rates at each stage of recruitment
The registry identified 468 cases of AYAs who met the
eligibility criteria. Of these 468 potentially eligible survi-
vors, clinicians reported that 57 did not meet the elig-
ibility criteria. Recruitment rates for the remaining 411
survivors, including rates within each stage of recruit-
ment, and rates for the overall sample, can be seen in
Figure 1. The overall consent rate for all potentially eli-
gible AYAs was 7.8% (n = 32).
Reasons for clinicians not providing consent to
contact survivors
Reasons reported by clinicians for not providing consent
for the registry to contact survivors are presented in
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did not meet the eligibility criteria for the study and
that 35% (n = 36) were no longer their patients.
Comparison of the final sample compared with the
overall sample
The demographic characteristics of AYAs who were
included and excluded at each stage of recruitment are
presented in Table 2. The final sample of participants was
reasonably representative, with no significant differences
between the proportions of males and females (p = 0.36) or
different cancer types (p = 0.14) for those who participated
and those who did not. However, there was a significant dif-
ference between the ages of the two groups, with those who
participated being significantly younger than those who
were unable to be contacted or did not consent (p < 0.01).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Survivors listed on registry who potentially met eligibility criteria n=468 
Registry contacted the cancer survivor’s clinician to gain consent for researchers 
to approach the patient 
Unable to contact clinician n=134  
(33% of all potentially eligible survivors) 
Clinician provided consent to contact n=232  
(56% of all potentially eligible survivors) 
Clinician did not provide consent n=45 
(11% of all potentially eligible survivors) 
Stage 1. 
 
Clinician 
provided 
consent to 
contact 
cancer 
survivor 
Stage 2. 
 
Cancer 
survivor 
consented to 
pass on 
contact details 
to researchers 
Stage 3. 
 
Cancer 
survivor 
consented to 
participate in 
study 
Unable to contact cancer survivor n=150 
(65% of those with clinician consent) 
(36% of all potentially eligible survivors) 
 Survivor did not return consent form n=18 
 (7.8% of those with clinician consent) 
(4.3% of all potentially eligible survivors)  
Registry contacted the 
cancer survivor to gain 
consent for researchers 
to approach them 
Survivor provided consent to contact n=64  
(28% of those with clinician consent) 
(16% of all potentially eligible survivors) 
Researchers included the survivor’s data in the research study 
Researchers contacted 
the cancer survivor to 
gain consent to 
participate in research 
Unable to contact cancer survivor n=12 
(19% of those who agreed to be contacted) 
(2.9% of all potentially eligible survivors) 
Survivor did not return questionnaire n=20 
 (31% of those who agreed to be contacted) 
(4.9% of all potentially eligible survivors)  
Survivor returned questionnaire n=32  
(50% of those who agreed to be contacted) 
(7.8% of all potentially eligible survivors) 
Clinician reported survivors ineligible n=57 
All potentially eligible 
survivors n=411 
Figure 1 Flowchart of the proportion of potentially eligible survivors filtered at each stage of recruitment.
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Summary of results
Despite the potential of the registry to access a large,
population-based sample of AYAs diagnosed with cancer,
only a small percentage (7.8%) of the potentially eligible
population was recruited into the study. Compared with
AYAs who were unable to be contacted or did not provide
consent, the resulting sample did not differ significantly by
gender or cancer type. However, compared with all poten-
tially eligible AYAs listed on the registry within the time
period of interest, a greater proportion of those recruited
into the study sample were 14 to 17 years of age. Given
the potential promise of registry recruitment to deliver
population-based, representative samples, it is important
to understand what factors may have contributed to these
low recruitment rates and potential sample bias.
Potential reasons for low recruitment rates and
non-representative samples
Clinician-related reasons
Clinicians no longer had contact with survivors
In the current study, over one-fifth of potential partici-
pants could not be contacted by the registry because
Table 1 Reasons provided by treating clinicians for not providing consent for the registry to contact survivors
Reason for refusal n = 102 %
Survivors did not meet eligibility criteria n = 57 (56%)
Not physically/mentally capable 12 12
Diagnosis not appropriate 11 11
<1 year life expectancy 9 8.8
Survivor did not wish to participate 7 6.8
Not in same state as registry 6 5.8
Situation not appropriate 6 5.8
Too ill 2 1.9
Doesn’t speak English 2 1.9
Survivor unaware of cancer diagnosis 2 1.9
Other reason n = 45 (44%)
Not current patient 36 35
No reason given 7 6.8
Clinician did not wish to participate 2 1.9
Table 2 Comparison of the final participant group with all other non-participants
Demographics of survivors
Stage 1 (n = 468) Stage 2 (n = 232) Stage 3 (n = 64) Total (n = 468)
Clinician did
not consent
(n = 102)
Unable to
contact
clinician
(n = 134)
Survivor did
not consent
(n = 18)
Unable to
contact
survivor
(n = 150)
Survivor did
not consent
(n = 20)
Unable to
contact
survivor
(n = 12)
Did not consent
and unable to
contact
(n = 436)
Final
participant
group (n = 32)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age at diagnosis
14-15 27 (26) 30 (22) 9 (50) 40 (27) 2 (10) 2 (17) 110 (25)* 11 (34)
16-17 27 (26) 51 (38) 2 (11) 46 (31) 8 (40) 6 (50) 140 (32) 16 (50)
18-19 48 (47) 53 (40) 7 (39) 64 (43) 10 (50) 4 (33) 186 (43)* 5 (16)
Gender
Female 44 (43) 59 (44) 7 (39) 68 (45) 4 (20) 8 (67) 190 (44) 17 (53)
Male 58 (57) 75 (56) 11 (61) 82 (55) 16(80) 4 (33) 246 (56) 15 (47)
Cancer type
Lymphoma 16 (16) 36 (27) 5 (28) 36 (24) 4 (20) 2 (17) 99 (23) 6 (19)
Skin 25 (25) 21 (16) 3 (17) 31 (21) 2 (10) 2 (17) 84 (19) 2 (6.2)
Testicular 9 (8.8) 13 (9.7) 0 (0) 13 (8.6) 4 (20) 0 (0) 39 (8.9) 1 (3.1)
Thyroid 11 (11) 7 (5.2) 0 (0) 11 (7.3) 2 (10) 1 (8.3) 32 (7.3) 3 (9.3)
Leukaemia 13 (13) 17 (13) 3 (17) 21 (14) 2 (10) 2 (17) 58 (13) 8 (25)
Other** 28 (27) 40 (30) 7 (39) 38 (25) 6 (30) 5 (42) 124 (28) 12 (38)
*Due to discrepancies in notified dates of diagnosis one non-participant may have been under 14 years of age and six non-participants may have been over 19 years
of age at diagnosis.
**"Other” includes cancers of brain, bone, connective tissue, colorectum, small intestine, kidney, liver, ovary, bladder, breast, lung and heart.
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survivor ineligibility was only cited as a reason for 56%
of these cases. For the majority of the remaining survi-
vors for whom clinician consent was not obtained, it
was because they were no longer current patients of the
clinician (35%). This situation may arise because regis-
tries receive cancer notifications from various sources
including pathology laboratories, survivors’ GPs, or can-
cer specialists [27,28]. Depending on the source of the
notification, the provider who is listed as the treating
clinician on the registry file may not be the person who
is overseeing the survivor’s cancer care. Factors such as
increasing population mobility[29,30] and an emphasis
on consumer satisfaction in health care[31] may also
mean that people are likely to change GPs as their
needs change. This may contribute to the lack of conti-
nuity in the doctor-patient relationship.
Clinicians did not respond
Almost a third (n = 134, 33%) of all identified potential
participants could not be contacted because their clini-
cians did not respond to correspondence from the
registry. Reasons for not responding can only be
hypothesised. However, one explanation may be that, as
outlined previously, the identified survivor was no
longer a current patient of the treating clinician.
Further, clinicians are veryt i m ep o o r[ 3 2 , 3 3 ] .T h i sf a c -
tor may be of particular importance when active clini-
cian consent is required by the registry. Others may feel
that responding to or participating in research studies is
not an important part of their professional role [34,35].
Members of particular professional groups or clinical
sub-specialities may have different attitudes towards
research participation, and this may in turn influence
the types of survivors who are permitted to be contacted
and who subsequently participate in the study [32,36].
Survivor-related reasons
Participants were unable to be contacted
Almost two-thirds (65%) of the 232 AYAs who received
their clinician’s consent to be approached by the registry
could not be contacted due to changed contact details.
Although this may present a problem for all retrospec-
tive studies recruiting through cancer registries, it may
be a particular problem when recruiting AYAs, as indi-
viduals in this age group are highly mobile [30,38]. In
Australia, half of all young people aged 15-24 years
moved residence during 1997 to 2001, with a large pro-
portion moving interstate [30]. This problem may not
be so prevalent for older survivor groups [39]. Austra-
lian registries can cross-check adult survivors’ names
and dates of birth with the electoral role and check for
changes of address. However, the same procedure can-
n o tb eu s e dt ou p d a t ec o n t a c ti n f o r m a t i o nf o rA Y A s
under the age of 18 years who are ineligible to vote.
Participants did not want to be contacted by the
researchers
It might be expected that the low participation rate
achieved was the result of lack of interest in the
research among AYAs. However, only a small number
of survivors refused to be contacted about the research
(n = 18, 7.8%). This suggests that being contacted for
participation in research studies is acceptable to this
survivor group.
Implication of low recruitment rates and non-
representative samples
There are ethical, research and cost related implications
of low recruitment rates and non-representative samples
achieved through registries using active clinician
consent.
Ethical implications
The process of seeking active clinician consent is under-
pinned by the ethical principle of beneficence. It is
implemented to minimise avoidable psychological harm
that survivors might experience by being contacted by
the registry [12,40]. However, in the current study the
main reasons for potential participants being excluded
at stage 1 of recruitment were related to clinicians no
longer having professional relationships with survivors,
or clinicians simply not responding. Forty-three percent
of all identified AYAs could not be approached due to
clinician refusal or non-response. This suggests that a
large proportion of survivors are being excluded for rea-
sons not related to study eligibility or emotional health,
indicating that the balance between the ethical princi-
ples of beneficence and patient autonomy may need to
be considered [12,41,42].
In weighing up these two ethical principles, the poten-
tial level of harm associated with the research and its
probability of occurrence need to be explored. It is gen-
erally accepted that most research studies will involve
some potential for harm [40,42]. Harm may range from
simple inconvenience to psychological distress, or in the
case of drug trials, unforseen side effects. Prior to com-
mencing a study, researchers need to provide a justifica-
tion to relevant ethics committees as to why the
potential benefits of their research outweigh any poten-
tial risks [40,42]. In many studies, risk of harm may be
small compared to the potential benefits of the research
[43-45].
Research implications
Participation in research may have benefits for both the
individual and the community. Patients who participate
in research studies may report better outcomes than
those who do not participate [46,47]. Survivors have
also reported valuing altruistic benefits of participation
[48]. Research may lead to improved outcomes for the
wider cancer population [49-52]. Therefore, it is
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with the potential research benefit to the individual and
to the wider cancer population [44,45,49].
If neither a high consent rate nor representative sam-
ple is obtained, the results of a study may not be gener-
alisable to the wider cancer population [53]. In this
study, the needs reported by the 32 AYAs who com-
pleted the questionnaire may not represent the needs of
the AYA population. The small sample size also meant
that there was limited statistical power to test hypoth-
eses or to validate the instrument developed for the
study.
Recruiting through more than one registry may be one
way to increase the sample size. However, if low consent
rates are achieved in all registries, the potential for bias
in the sample remains. Other issues including the bur-
den of gaining approval from numerous cancer registry
ethics committees, as well as the cost of research and
registry personnel, would also need to be taken into
account [54].
Cost-related implications
There are high public and individual costs involved in
conducting research. The vast majority of research is
publicly funded through either large government organi-
sations such as the National Cancer Institute (NCI) in
the United States and the National Health and Medical
Research Council (NHMRC) in Australia, or through
charitable organisations [55,56]. For this reason, it is of
paramount importance that the public gets a good
return on investment. However, the process of recruit-
ment through registries, especially when active clinician
consent is required, can be expensive in terms of time,
energy and resources[54], and for some population
groups may not be cost-efficient. In the present case
where only 32 AYAs were recruited from 411 potentially
eligible AYAs, the enormous staff and material costs of
the research appear to be out of proportion to the num-
ber of participants recruited and usefulness of the of
data collected.
There are also costs to individual clinicians and sur-
vivors who participate. The active consent protocol
adds an additional burden to already time-poor clini-
cians [54]. This would appear to be an inefficient use
of time for both the registry and the clinician, particu-
larly if clinicians no longer have contact with these
survivors [12].
Furthermore, the active consent protocol places a bur-
den on survivors. In the current study, there is a cost to
the 32 AYAs who participated. Despite the time and
effort expended by participants, it is difficult to do any-
thing meaningful with their data due to the low overall
response rate. In light of the cost and limited usefulness
of the data obtained, it may be important to explore
possible alternatives that could be used to overcome
these low consent rates.
Resource efficient alternatives for achieving
representative research samples
There are a number of alternative protocols which could
be considered as feasible options when attempting to
recruit population-based samples through cancer
registries.
Passive clinician consent
T h er e g i s t r yi n v o l v e di nt h ec u r r e n ts t u d yr e q u i r e dt h e
use of an active clinician consent protocol, however,
some registries allow passive clinician consent [12,13].
Passive clinician consent may help to reduce the burden
placed on clinicians and has been used successfully by a
number of international registries and studies [12,13].
However, given the fact that many clinicians may no
longer have contact with AYA survivors, this method
may still not be viable.
Other approaches could involve the registry giving
clinician and survivor details directly to researchers who
then make the initial contact with the clinician, instead
of the registry. Over 60% of cancer registries in the
United States use this approach [12]. The majority of
registries using this researcher-initiated protocol require
passive clinician consent (70% of registries) and a survi-
vor opt-out approach (86% of registries) [12]. However,
in Australia, because registries are usually notified under
a Public Health Act, information cannot be provided to
a third party without survivor consent. Furthermore, the
process of researchers notifying a survivor’sc l i n i c i a n
prior to contacting the survivor about a research study
may still be viewed as paternalistic. Beskow and collea-
gues reported that over two-thirds of patients (68%) said
that they preferred that researchers contact them
directly about opportunities for research participation,
rather than checking with their physicians first [57].
Therefore, alternatives to a passive clinician consent
model should be explored.
Direct survivor consent
A novel method for assisting registries to provide cancer
survivors with information about research studies for
which they may be eligible could be through direct sur-
vivor contact [57,58]. This might involve a one-off con-
tact with a survivor by the registry which would allow
the survivor to indicate whether or not they would like
to be contacted about research studies in the future, the
types of research they would like to be contacted about,
and how often these contacts could be made [5]. This
consumer driven approach would allow survivors to
choose the focus of research studies they are interested
in participating in and negate the need for clinician con-
sent to contact the survivors.
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although 82% of participants did not know the registry
existed, 95% thought that the information collected was
useful [58]. Over 80% of respondents indicated that the
collection personal information by the registry and the
use of the registry for recruitment purposes was accep-
table. In anticipation of low survivor awareness of the
registry and its role, cancer registries could send an
information leaflet as part of their initial contact with
survivors.
Recruitment of AYAs via treatment centres and clinics
Direct consumer contact may provide greater survivor
autonomy and overcome low clinician response rates.
However, this method may not overcome difficulties
associated with obtaining up-to-date contact details of
survivors. Recruitment of AYAs from treatment centres
and clinics may potentially address this problem. Due to
the low prevalence of cancer in AYAs, recruitment from
a number of different clinics is likely to be required in
order to achieve a sufficiently large and representative
sample. A number of AYA research studies have suc-
cessfully used this method of recruitment [59,60]. One
complication may be the need to target both adult and
children’s hospitals to obtain a sample which adequately
covers the age range of the AYA population.
Limitations
Limitations should be considered when interpreting the
findings of the current study. First, recruitment was only
conducted through one state registry in Australia.
Therefore, it is possible that the low recruitment rates
obtained may have been specific to this registry. How-
ever, studies which have compared recruitment rates
between registries using active or passive clinician con-
sent have generally found that recruitment rates are
lower in registries requiring active consent [13]. Second,
62% of AYAs who consented and could be contacted
returned a completed survey. It is possible that tele-
phone administered or online surveys might have been
more acceptable to this group than the paper and pencil
format that was used. However, some studies using
online methods of data collection with this population
have also resulted in small sample sizes [61].
Conclusions
Despite the potential for cancer registries to provide
researchers with access to large and representative sam-
ples, current registry protocols such as active clinician
consent may inhibit this process. Alternative methods
such as passive clinician consent or direct survivor con-
sent may help to overcome some of these barriers. In the
case of AYAs diagnosed with cancer who are highly
mobile, recruitment through registries may not be
feasible and other alternatives, such as recruitment
through treatment centres and clinics, may need to be
considered.
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